Abbott will take over marketing and distributing the product. The company acquired Kos Pharmaceuticals at the end of 2006. Merck entered into an agreement in 2002 with Kos of Miami, Florida, for marketing rights to Niaspan worldwide excluding North America and Japan.
Merck sales of Niaspan in 2006 were EUR 7.0 million.